Novartis licenses rights to RNA-targeting cardio drug from Ionis

Swiss drugmaker Novartis said on Monday it is exercising its option to license rights to an investigational, RNA-targeting cardiovascular drug from Ionis Pharmaceuticals as it targets inherited factors that have defied other treatments.

from Reuters: Health News https://ift.tt/2H173pd